Marker Therapeutics (MRKR) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Marker Therapeutics (MRKR) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 33.30% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 78.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 81.16% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -35.50% |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190.82% |
| Dec 31, 2025 | 39.02% |
| Jun 30, 2025 | -925.03% |
| Dec 31, 2024 | -19.67% |
| Sep 30, 2024 | -25.46% |
| Jun 30, 2024 | -41.21% |
| Mar 31, 2024 | 48.79% |
| Dec 31, 2023 | 63.73% |
| Sep 30, 2023 | 18.36% |
| Jun 30, 2023 | -161.45% |
| Mar 31, 2023 | 84.12% |
| Dec 31, 2022 | -33.46% |
| Sep 30, 2022 | 71.11% |
| Jun 30, 2022 | 75.99% |
| Mar 31, 2022 | 32.48% |
| Dec 31, 2021 | 4.32% |
| Dec 31, 2020 | 9.85% |
| Sep 30, 2019 | -35.57% |
| Sep 30, 2016 | -259.92% |
| Sep 30, 2014 | 33.66% |